NCT05522868 SB17170 Phase 1 Clinical Trial in Solid Tumors
| NCT ID | NCT05522868 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | SPARK Biopharma |
| Condition | Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-10-17 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 50 participants in total. It began in 2022-10-17 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
Eligibility Criteria
Inclusion Criteria: * A patient with a histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors. * A person who has failed the known standard of care or has developed resistance to the standard of care and no longer has applicable standard of care * A patient with at least one measurable lesion according to the RECIST v1.1 criteria. * A person with Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1. * Those with an expected survival period of 3 months or more at the discretion of of the investigator. Exclusion Criteria: * A patient who has received drugs targeting High Mobility Group Box 1 (HMGB1). * A patient who has received or is undergoing chemotherapy (including chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted therapy, biological products, and tumor embolization) within 28 days from the first administration date of the investigational drug. * A person who needs to take contraindicated drugs or is expected to take them during the study period.
Contact & Investigator
Soojin Jun
STUDY DIRECTOR
SPARK Biopharma
Frequently Asked Questions
Who can join the NCT05522868 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05522868 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05522868 currently recruiting?
Yes, NCT05522868 is actively recruiting participants. Contact the research team at sbkang@sparkbio.co.kr for enrollment information.
Where is the NCT05522868 trial being conducted?
This trial is being conducted at Seoul, South Korea, Seoul, South Korea, Seoul, South Korea.
Who is sponsoring the NCT05522868 clinical trial?
NCT05522868 is sponsored by SPARK Biopharma. The principal investigator is Soojin Jun at SPARK Biopharma. The trial plans to enroll 50 participants.